Supernus Pharmaceuticals reported Q3 2021 total revenues of $148.5 million, a 4% decrease compared to $155.1 million in Q3 2020. Net earnings were $21.6 million, or $0.40 per diluted share, compared to $40.0 million, or $0.74 per diluted share, for the same period in 2020.
Total revenues for Q3 2021 were $148.5 million, a 4% decrease compared to Q3 2020.
Operating earnings for Q3 2021 were $32.6 million, compared to $56.1 million for the same period in 2020.
Net earnings for Q3 2021 were $21.6 million, compared to $40.0 million for the same period in 2020.
The company expects to resubmit the SPN-830 NDA to the FDA in November 2021.
The Company increases its financial guidance for operating earnings, lowers its financial guidance for total combined R&D and SG&A expenses, and lowers the top end of its financial guidance range for total revenues for full year 2021.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance